Clinical Research Directory

Inclusion Criteria: * Patients with severe secondary MR characterized, according to the European guidelines and recommendations, by a regurgitant volume ≥30 mL/beat or an effective regurgitant orifice ≥20 mm². * Symptomatic patients with New York Heart Association Class ≥II. * Left ventricular ejection fraction between 15% and 50%. * Optimal standard of care therapy for heart failure according to investigator. * Not eligible for a mitral surgery intervention according to the Heart Team. * Patients who have the ability to understand the requirements of the study and provide written consent/assent to participate and agree to abide by the study requirements. Exclusion Criteria: * Participants younger than 18 years * Pregnancy or breastfeeding * Severe impaired renal function (GFR \< 15 ml/min) * Patients with untreated severe concomitant valve disease (e.g. severe tricuspid valve regurgitation, aortic stenosis) * The patient has a medical condition, serious concurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up * The patient has contraindications to CMR, including: Implanted non-CMR conditional metallic implants, pacemaker, intracardiac defibrillator, neurostimulator, epicardial pacemaker leads, or any abandoned leads, ferromagnetic aneurysm clip, ferromagnetic halo device, cochlear implants, implanted infusion pumps or severe claustrophobia * The patient is clinically unstable or has stage D congestive heart failure or inability to lay flat for 60 minutes